Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Cytokinetics Incorporated, 3 years.
Cytokinetics Incorporated
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Cytokinetics Incorporated May 14, 202585.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 15, 2026 | Cytokinetics Incorporated | Grant or award | +272 | $82.62 | $22,473 |
| May 27, 2026 | Cytokinetics Incorporated | Grant or award | +2,851 | — | — |
| May 5, 2026 | Cytokinetics Incorporated | Option exercise | +20,000 | $7.61 | $152,200 |
| May 5, 2026 | Cytokinetics Incorporated | Open-market sale | −20,000 | $75.97 | $1,519,400 |
| Apr 15, 2026 | Cytokinetics Incorporated | Grant or award | +325 | $65.37 | $21,245 |
| Jan 15, 2026 | Cytokinetics Incorporated | Grant or award | +334 | $63.44 | $21,189 |
| Dec 2, 2025 | Cytokinetics Incorporated | Option exercise | +8,750 | $10.00 | $87,500 |
| Dec 2, 2025 | Cytokinetics Incorporated | Open-market sale | −8,750 | $63.90 | $559,125 |
| Oct 15, 2025 | Cytokinetics Incorporated | Grant or award | +338 | $62.80 | $21,226 |
| Jul 15, 2025 | Cytokinetics Incorporated | Grant or award | +559 | $38.01 | $21,248 |
| May 14, 2025 | Cytokinetics Incorporated | Grant or award | +7,333 | — | — |
| Apr 15, 2025 | Cytokinetics Incorporated | Option exercise | +20,000 | $6.21 | $124,200 |
| Apr 15, 2025 | Cytokinetics Incorporated | Grant or award | +551 | $38.56 | $21,247 |
| Apr 15, 2025 | Cytokinetics Incorporated | Open-market sale | −3,190 | $38.66 | $123,325 |
| Jan 2, 2025 | Cytokinetics Incorporated | Grant or award | +434 | $48.93 | $21,236 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.